Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04485195
Other study ID # 20200402
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date June 17, 2021
Est. completion date June 1, 2024

Study information

Verified date September 2023
Source Ottawa Hospital Research Institute
Contact Ian G Stiell, MD, MSc
Phone 613-798-5555
Email istiell@ohri.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective is to compare IV vernakalant to IV procainamide for the ED management of acute AF patients. If vernakalant proves to be more effective, faster, and safer than IV procainamide, this will give clinicians an important alternative for pharmacological cardioversion of acute AF. The investigators propose a pragmatic comparative effectiveness trial entailing an open label, randomized controlled trial at 12 large Canadian EDs. Study subjects will be randomized to 1 of 2 treatment arms: 1) Patients will receive an initial infusion of 3mg/kg of IV vernakalant over 10 minutes, followed by a second dose of 2mg/kg over 10 minutes, if necessary, or 2) Patients will receive a continuous infusion of 15mg/kg of IV procainamide over 60 minutes. The primary aim will be to compare conversion to normal sinus rhythm between the two drugs. The investigators will include stable patients presenting with an episode of acute AF of at least 3 hours duration, where symptoms require urgent management and where immediate cardioversion is a reasonable option. Using the integrated consent model, research assistants will obtain verbal consent from eligible patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 340
Est. completion date June 1, 2024
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: The investigators will include stable (see below) patients presenting with an episode of acute non-valvular AF of at least 3 hours duration and no greater than 7 days, where symptoms require urgent management and where immediate cardioversion is a reasonable option because: 1. The patient has been adequately anticoagulated for a minimum of 3 weeks (warfarin and INR > 2.0 or novel oral anticoagulants [dabigatran, rivaroxaban, edoxaban, and apixaban]), or 2. The patient is not adequately anticoagulated for > 3 weeks, has no history of stroke or TIA, and does not have valvular heart disease, AND: i) onset < 12 hours ago, or ii) if onset 12 - 48 hours ago and there are <2 of these CHADS-65 criteria (age = 65, diabetes, hypertension, heart failure), or iii) negative for thrombus on transesophageal echocardiography. Of note, we will not exclude patients with prior episodes of acute AF. Patients will only be enrolled if the attending physician is confident about time of onset, based upon the patient's symptoms. Physicians are well aware of the importance of this determination and will not attempt to cardiovert patients otherwise. Exclusion Criteria: The investigators will exclude patients who have any of the reasons listed below. 1. Appropriateness: 1. unable to understand the study and integrated consent due to language barrier and/or cognitive impairment; 2. have permanent (chronic) AF; 3. have valvular heart disease (mitral stenosis, rheumatic or mechanical); 4. increased risk of stroke because onset not clearly <48 hours and not anticoagulated (or abnormal TEE); or do not meet the inclusion criteria a or b; 5. deemed unstable and require immediate cardioversion: i) systolic blood pressure <100 mmHg; ii) rapid ventricular preexcitation (Wolff-Parkinson-White syndrome); iii) acute coronary syndrome - chest pain and acute ischemic changes on ECG; or iv) pulmonary edema - severe dyspnea requiring immediate IV diuretic, nitrates, or BIPAP; 6. primary presentation was for another condition; examples include pneumonia, pulmonary embolism, and sepsis; 7. convert spontaneously to sinus rhythm prior to randomization; 8. were previously enrolled in the study; or 9. have atrial flutter. 2. Safety 1. has heart failure Class NYHA III or NYHA IV; left ventricular ejection fraction <30%; or has clinical or radiological evidence of acute HF; 2. has presented with an acute coronary syndrome or acute decompensated heart failure, in the last 30 days; or has had a recent myocardial infarction (< 3 months); 3. has severe aortic stenosis; 4. has a systolic blood pressure < 100 mmHg; 5. has a significantly prolonged QT interval at baseline e.g. uncorrected > 440 msec, congenital or acquired long QT syndrome; or a family history of Long QT syndrome; or ECG shows QTc >460ms (when heart rate >100 measured by the Fridericia formula); 6. has severe bradycardia (heart rate < 55 bpm), sinus node dysfunction, or second or third degree atrioventricular heart block, in the absence of an in situ properly functioning pacemaker; or, has Brugada syndrome (genetic disease with increased risk of sudden cardiac death); 7. has received an intravenous antiarrhythmic drug Class I, e.g. procainamide, or Class Ill, e.g. amiodarone or ibutilide, within the prior 4 hours; or currently takes oral class I or III antiarrhythmic drugs other than amiodarone (last dose < 5 half-lives before enrollment); 8. has received an IV beta-blocker within the 2 hours prior 9. has hypersensitivity to the active substance or to any of the ingredients of either drug; 10. has advanced or end-stage liver disease; or 11. is breast feeding or pregnant (safety not established).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vernakalant
an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump
Procainamide
15 mg/kg in 500 mL of normal saline given over 60 minutes

Locations

Country Name City State
Canada University of Alberta Hospital Edmonton Alberta
Canada Queen Elizabeth II Health Sciences Centre Halifax Nova Scotia
Canada Hamilton Health Sciences Centre Hamilton Ontario
Canada Kingston Health Sciences Centre Kingston Ontario
Canada Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval Laval Quebec
Canada Hopital Du Sacre-Coeur Montreal Quebec
Canada Montreal Heart Institute Montreal Quebec
Canada Ottawa Hospital Ottawa Ontario
Canada Hôtel-Dieu de Lévis Québec Quebec
Canada Hopital de L'Enfant-Jesus Quebec City Quebec
Canada St. Michaels Toronto Ontario
Canada Sunnybrook Hospital Toronto Ontario
Canada St. Paul's Hospital Vancouver British Columbia
Canada Vancouver General Hospital Vancouver British Columbia

Sponsors (1)

Lead Sponsor Collaborator
Ottawa Hospital Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Maintenance of normal sinus rhythm Maintenance of normal sinus rhythm at 30 days after ED disposition, to be verified by hospital records, patient report, or by a smartphone application. 30 days post discharge
Other Recurrence of acute AF Recurrence of acute atrial fibrillation requiring an emergency department visit 30 days
Other Death within 30 days of ED disposition 30 days
Other Stroke transient ischemic attack, myocardial infarction, or other thromboembolic event within 30 days of ED disposition 30 days
Other Return to normal activities Return to normal daily activities measured in days 30 days
Primary Conversion to sinus rhythm for a minimum duration of 30 minutes Conversion to and maintenance of sinus rhythm for at least 30 minutes at any time following randomization until 30 minutes past the completion of the drug infusion. Heart rhythm will be determined by an electrocardiogram (ECG). During any time following randomization until 30 minutes past the completion of the drug infusion
Secondary Normal sinus rhythm Being in normal sinus rhythm at the time of ED disposition (discharge or admission). Heart rhythm will be determined by an electrocardiogram (ECG). At the time of patient disposition (approximately 3 hours after arrival)
Secondary Patient disposition (admission or discharge) Whether the patient was discharged home or admitted to the hospital. At the time of patient admission or discharge (approximately 3 hours after arrival)
Secondary Length of stay in ED Length of stay in ED in minutes, from time of arrival to time of discharge or admission From time of arrival until time of discharge or admission (approximately 3 hours)
Secondary Time to discharge Time to discharge in minutes, from time of randomization to time of discharge or admission From time of randomization until time of discharge or admission (approximately 3 hours)
Secondary Time to conversion Time to conversion to sinus rhythm in minutes, from time of start of study drug infusion From time of infusion start until time of conversion to sinus rhythm (approximately 0 - 90 minutes)
Secondary Whether the patient required electrical cardioversion Whether the patient required electrical cardioversion to restore normal sinus rhythm in the ED From 30 minutes after the study drug infusion is completed.
Secondary Adverse events will be classified as serious or other, whether occurring 0-2 hours or 2-12 hours after infusion, whether infusion had to be halted or discontinued, or treatment required 0-12 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A